ALENDRONATE ON BONE DENSITY MAINTENANCE IN FEMALE NURSING HOME PATIENTS
Funded Grant
Overview
Affiliation
View All
Overview
description
Part I is designed to evaluate the effect of tiludronate on the vertebral fracture rate of postmenopausal women with established osteoporosis and low bone mass by measuring the incidence of vertebral fracture events after two years of treatment. Part II is designed to evaluate the effect of tiludronate on bone mineral density of postmenopausal women with low bone mass and no vertebral fractures.
The double-blind, placebo-controlled, randomized clinical trial will determine the efficacy of a new bisphosphonate, Fosamax, to prevent bone loss in women with an acute hip fracture. Bone mineral density of all sites and biochemical markers of bone loss will be assessed over six months.
This double-blind, placebo-controlled, randomized, 4-arm clinical trial is designed to examine the efficacy of bisphosphonate +/- estrogen replacement therapy in the maintenance of femoral skeletal integrity in women over 65 years old. Outcome variables will include bone mineral density, biochemical markers, ultrasound and new assessments of bone strongth.
This multicenter prospective study is designed to establish the effect of long-term therapy with raloxifene hydrochloride on lumbar spine and hip bone mineral density in healthy, postmenopausal, hysterectomized women versus placebo versus Premarin on biochemical markers of bone metabolism in the same patients; and to establish the safety of chronic administration of the drug.
This multicenter prospective trial is designed to determine the safety and efficacy of therapy with a growth hormone secretagogue MK-0677 alone and in combination with alendronate on bone turnover and bone mineral density in women with postmenopausal osteoporosis.
This prospective multicenter protocol evaluates the safety, tolerability and efficacy of alendronate, conjugated estrogen and combined therapy to determine if treatment with the combined therapy will produce a significantly greater mean increase in lumbar spine bone mineral density at two years over conjugated estrogen therapy alone in females with postmenopausal bone loss.
This two-year multicenter trial will investigate the safety and efficacy of the bisphosphonate, alendronate, in the treatment of osteoporosis in older women living in a long-term care facility.
To determine if treatment for one year with oral alendronat 35 mg. once weekly will produce increases in lumbar spine bone mineral density; and to assess the safety and tolerability of this dose.
To determine if treatment for one year with oral alendronate weekly will produce increases in lumbar spine bone mineral density; and to assess the safety and tolerability of 35 mg. and 70 mg. doses in postmenopausal, osteoporotic women.
To determine the incidence of the hereditary condition, Gaucher disease, among patients with low platelet counts, low bone mass, and/or a history of bone fractures. Participation will assist physicians in more accurately diagnosing patients with Gaucher disease.
